Cellectis announces Q3 adjusted EPS of 2 cents compared to a loss of 22 cents in the previous year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Q3 Revenue Growth: Cellectis reported a Q3 revenue of $35.17 million, a significant increase from $16.2 million in the previous year.
Clinical Program Success: CEO Andre Choulika highlighted promising data from their lasme-cel and eti-cel programs, indicating potential improvements in treating high unmet medical needs in r/r B-ALL and r/r NHL.
Upcoming Milestones: Cellectis plans to share further updates on the eti-cel program at the ASH 2025 Annual Meeting and expects to provide the first interim analysis for the pivotal Phase 2 BALLI-01 trial in Q4 2026.
Leadership in CAR-T Innovation: These developments are positioned to strengthen Cellectis's leadership in allogeneic CAR-T innovation, setting the stage for a transformative year ahead.
Analyst Views on CLLS
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 7.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.370
Low
4.00
Averages
7.00
High
9.00
Current: 4.370
Low
4.00
Averages
7.00
High
9.00
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
